For people with type 2 diabetes and obesity, guidelines increasingly favor choosing GLP-1-based agents early in the treatment regimen, particularly when weight and cardiorenal risk are central goals
It is not a licensed medicine: Wegovy remains the sole semaglutide product approved for human weight-loss use in the UK as of 2026 [4][6], and all consumer-facing semaglutide supply is prescription-only under MHRA enforcement [3]
Cons of Semaglutide: Less Dramatic Weight Loss: The amount of weight loss varies considerably, and it's usually less than with bariatric surgery
Doctors respond better to informed patients who ask specific questions than to patients who just say they want a specific drug
Many patients report improved energy and reduced fatigue as their appetite and metabolism become more balanced
On the other hand, based on his chronic use of HGH, an increased ventricular mass and acromegaly related cardiomyopathy might had been accountable for the sudden cardiac arrest
